<DOC>
	<DOCNO>NCT01910909</DOCNO>
	<brief_summary>1 . Background 1.1 . Hepatocellular carcinoma ( HCC ) HCC third common cause cancer death globally . It also second cause cancer mortality Korea , despite incidence HCC fifth . The important cause discrepancy connect fact significant portion HCC detect unresectable status . 1.2 . Standard treatment HCC At point HCC diagnosis , 30 % patient could receive standard curative treatment , like resection , liver transplantation , radiofrequency ablation ( RFA ) . Transcatheter arterial chemoembolization ( TACE ) show randomized trial improve survival compare symptomatic therapy alone , patient without macrovascular involvement , extrahepatic disease tumor relate symptom . However , recent review TACE , TACE might contraindicate recommended patient show vascular tumor invasion , 10 cm size , poor portal blood flow and/or repeat poor response . Recently , Sorafenib , one target agent , show survival advantage unresectable HCC patient two randomize study . In study , sorafenib improve approximately three month overall survival increment , however , median survival duration 10.7 month experiment group ( receive sorafenib ) , even 6.5 month Asian-Pacific trial . Additionally , possibility sorafenib effect could reduce patient hepatitis B virus ( HBV ) suggest subgroup analysis . 1.3 Radiation therapy ( RT ) HCC The use RT HCC increase radiation technological advance . In unresectable patient , RT show 50 60 % response rate dose response relationship . Recently , stereotactic body radiation therapy ( SBRT ) show excellent local control comparable survival rate thoracic tumor . In HCC , SBRT also show 75 100 % local control rate without significant elevation toxicity . One study report 24 54 Gy SBRT achieve 87 % 1year local control 17 month overall survival . The standard treatment unresectable HCC sorafenib , Korean Liver Cancer Study Group ( KLCSG ) recommend RT option localize unresectable HCC . Furthermore , Radiation Therapy Oncology Group ( RTOG ) start randomize trial confirm effect SBRT unresectable HCC ( RTOG 1112 ) . Investigators previously report retrospective result high dose SBRT achieve 2 year overall survival 87.9 % local control 85 % patient show less 5 cm solitary HCC without portal vein involvement . Based study , start prospective study evaluate effectiveness adverse event SBRT patient solitary 3 cm less size HCC without extrahepatic lesion vascular involvement .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Patients must diagnosis HCC least one criterion list ( KLCSG guideline 2009 ) 1.1 Pathologically ( histologically cytologically ) proven diagnosis HCC 1.2 Liver nodule high risk group 1.2.1 If alpha feto protein ( AFP ) ≥200 ng/mL , ≥ 1 typical HCC enhance pattern dynamic contrast enhance CT MRI 1.2.2 If AFP &lt; 200 ng/mL , ≥2 typical HCC enhance pattern dynamic contrast enhance CT , MRI , angiography 1.3 ≥ 2 cm nodule liver cirrhosis ( LC ) , ≥ 1 typical HCC enhance pattern dynamic contrast enhance CT MRI 2 . Eastern cooperative oncology group performance status 0 1 3 . Size HCC ≤ 3 cm less 4 . Age ≥ 20 5 . Unsuitable resection transplant RFA 6 . Unsuitable refractory TACE drug elute bead ( DEB ) 7 . Agreement studyspecific inform consent 8 . Assessment radiation oncologist medical oncologist hepatologist within 28 day prior study entry ? 9 . ChildPugh score A within 14 day prior study entry 10. normal liver ( Liver minus gross tumor volume ) ≥ 700 cc 11 . Target one viable hepatocellular carcinoma 12 . Blood work requirement Absolute neutrophil count ( ANC ) ≥ 1,500 /mm3 , Platelet ≥ 70,000/mm3 , Hgb ≥ 8 g/dl Liver function test ( LFT ) : T. bilirubin &lt; 3.0 mg/dL , International normalize ratio ( INR ) &lt; 1.7 , Albumin ≥ 2.8g/dL , Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) &lt; 6 X normal Serum creatinine &lt; 1.5 X normal , Creatinine clearance rate ≥ 60 mL/min 13 . Male , consent contraception least 6 month Childbearing potential woman , consent contraception least 6 month 14 . Life expectancy 12 week 15 . Stable breathe 10 minute 16 . Consent fiducial marker insertion ( need ) 1 . Extrahepatic metastasis malignant nod 2 . Pregnant and/or breastfeed woman 3 . Macroscopic vascular tumor involvement 4 . Previous upper abdominal RT history 5 . Uncontrolled active comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>unresectable</keyword>
	<keyword>small size</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
</DOC>